Acute Kidney Injury: Tubular Markers and Risk for Chronic Kidney Disease and End-Stage Kidney Failure

Blood Purification

Volumn 41, Issue 1-3, 2016, Pages 144-150

  Tan, Hon Liang ^a   Yap, John Q ^b   Qian, Qi ^a  

^a Mayo Clinic   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

Acute kidney injury; Biomarkers; Chronic kidney diseases; Differential diagnosis; End stage renal failure; Prognosis

Indexed keywords

ADENOSINE RECEPTOR; BIOLOGICAL MARKER; FATTY ACID BINDING PROTEIN; INTERLEUKIN 18; KIDNEY INJURY MOLECULE 1; LIVER TYPE FATTY ACID BINDING PROTEIN; N(G),N(G) DIMETHYLARGININE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; SOMATOMEDIN BINDING PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNCLASSIFIED DRUG; ADENOSINE A2 RECEPTOR;

ACUTE KIDNEY FAILURE; AUTOPHAGY; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DEDIFFERENTIATION; CELL INTERACTION; CHRONIC KIDNEY DISEASE; CONFERENCE PAPER; DENDRITIC CELL; DIFFERENTIAL DIAGNOSIS; DISABILITY SEVERITY; DISEASE COURSE; END STAGE RENAL DISEASE; FIBROSING ALVEOLITIS; HUMAN; INNATE IMMUNITY; KIDNEY TUBULE DISORDER; PATHOPHYSIOLOGY; PERICYTE; PHENOTYPE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; ACUTE KIDNEY INJURY; ENDOTHELIUM CELL; G2 PHASE CELL CYCLE CHECKPOINT; KIDNEY FAILURE, CHRONIC; KIDNEY TUBULE; METABOLISM; PATHOLOGY; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR;

ACUTE KIDNEY INJURY; BIOMARKERS; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; ENDOTHELIAL CELLS; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TUBULES; PERICYTES; PROGNOSIS; RECEPTORS, ADENOSINE A2; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 84954434563     PISSN: 02535068     EISSN: 14219735     Source Type: Journal    
DOI: 10.1159/000441269     Document Type: Conference Paper

References (96)

1. Ali T, Khan I, Simpson W, et al: Incidence and outcomes in acute kidney injury: A comprehensive population-based study. J Am Soc Nephrol 2007; 18: 1292-1298.
2. Singbartl K, Kellum JA: AKI in the ICU: definition, epidemiology, risk stratification, and outcomes. Kidney Int 2012; 81: 819-825.
3. Leung KC, Tonelli M, James MT: Chronic kidney disease following acute kidney injury-risk and outcomes. Nat Rev Nephrol 2013; 9: 77-85.
4. Linder A, Fjell C, Levin A, Walley KR, Russell JA, Boyd JH: Small acute increases in serum creatinine are associated with decreased long-term survival in the critically ill. Am J Respir Crit Care Med 2014; 189: 1075-1081.
5. Hsu CY, Chertow GM, McCulloch CE, Fan D, Ordonez JD, Go AS: Nonrecovery of kidney function and death after acute on chronic renal failure. Clin J Am Soc Nephrol 2009; 4: 891-898.
6. Venkatachalam MA, Griffin KA, Lan R, Geng H, Saikumar P, Bidani AK: Acute kidney injury: A springboard for progression in chronic kidney disease. Am J Physiol Renal Physiol 2010; 298:F1078-F1094.
7. Ishani A, Xue JL, Himmelfarb J, et al: Acute kidney injury increases risk of ESRD among elderly. J Am Soc Nephrol 2009; 20: 223-228.
8. Coca SG, Yusuf B, Shlipak MG, Garg AX, Parikh CR: Long-term risk of mortality and other adverse outcomes after acute kidney injury: A systematic review and meta-analysis. Am J Kidney Dis 2009; 53: 961-973.
9. Perazella MA, Coca SG, Kanbay M, Brewster UC, Parikh CR: Diagnostic value of urine microscopy for differential diagnosis of acute kidney injury in hospitalized patients. Clin J Am Soc Nephrol 2008; 3: 1615-1619.
10. Perazella MA, Coca SG, Hall IE, Iyanam U, Koraishy M, Parikh CR: Urine microscopy is associated with severity and worsening of acute kidney injury in hospitalized patients. Clin J Am Soc Nephrol 2010; 5: 402-408.
11. Carvounis CP, Nisar S, Guro-Razuman S: Significance of the fractional excretion of urea in the differential diagnosis of acute renal failure. Kidney Int 2002; 62: 2223-2229.
12. Pepin MN, Bouchard J, Legault L, Ethier J: Diagnostic performance of fractional excretion of urea and fractional excretion of sodium in the evaluations of patients with acute kidney injury with or without diuretic treatment. Am J Kidney Dis 2007; 50: 566-573.
13. Bagshaw SM, Bennett M, Devarajan P, Bellomo R: Urine biochemistry in septic and nonseptic acute kidney injury: A prospective observational study. J Crit Care 2013; 28: 371-378.
14. Darmon M, Vincent F, Dellamonica J, et al: Diagnostic performance of fractional excretion of urea in the evaluation of critically ill patients with acute kidney injury: A multicenter cohort study. Crit Care 2011; 15:R178.
15. Langenberg C, Wan L, Bagshaw SM, Egi M, May CN, Bellomo R: Urinary biochemistry in experimental septic acute renal failure. Nephrol Dial Transplant 2006; 21: 3389-3397.
16. Bagshaw SM, Haase M, Haase-Fielitz A, Bennett M, Devarajan P, Bellomo R: A prospective evaluation of urine microscopy in septic and non-septic acute kidney injury. Nephrol Dial Transplant 2012; 27: 582-588.
17. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P; Acute Dialysis Quality Initiative Workgroup: Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8:R204-R212.
18. Mehta RL, Kellum JA, Shah SV, et al: Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11:R31.
19. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group: KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2012; 2: 1-138.
20. Alge JL, Arthur JM: Biomarkers of AKI: A review of mechanistic relevance and potential therapeutic implications. Clin J Am Soc Nephrol 2015; 10: 147-155.
21. Humphreys BD, Xu F, Sabbisetti V, et al: Chronic epithelial kidney injury molecule-1 expression causes murine kidney fibrosis. J Clin Invest 2013; 123: 4023-4035.
22. Bolignano D, Lacquaniti A, Coppolino G, et al: Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 337-344.
23. Hvidberg V, Jacobsen C, Strong RK, Cowland JB, Moestrup SK, Borregaard N: The endocytic receptor megalin binds the iron transporting neutrophil-gelatinase-associated lipocalin with high affinity and mediates its cellular uptake. FEBS Lett 2005; 579: 773-777.
24. Paragas N, Qiu A, Zhang Q, et al: The NGAL reporter mouse detects the response of the kidney to injury in real time. Nat Med 2011; 17: 216-222.
25. Goetz DH, Holmes MA, Borregaard N, Bluhm ME, Raymond KN, Strong RK: The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell 2002; 10: 1033-1043.
26. Flo TH, Smith KD, Sato S, et al: Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 2004; 432: 917-921.
27. Mishra J, Mori K, Ma Q, et al: Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 2004; 15: 3073-3082.
28. Mori K, Lee HT, Rapoport D, et al: Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest 2005; 115: 610-621.
29. Ko GJ, Grigoryev DN, Linfert D, et al: Transcriptional analysis of kidneys during repair from AKI reveals possible roles for NGAL and KIM-1 as biomarkers of AKI-to-CKD transition. Am J Physiol Renal Physiol 2010; 298:F1472-F1483.
30. Bolignano D, Coppolino G, Lacquaniti A, Nicocia G, Buemi M: Pathological and prognostic value of urinary neutrophil gelatinaseassociated lipocalin in macroproteinuric patients with worsening renal function. Kidney Blood Press Res 2008; 31: 274-279.
31. Yang YH, He XJ, Chen SR, Wang L, Li EM, Xu LY: Changes of serum and urine neutrophil gelatinase-associated lipocalin in type-2 diabetic patients with nephropathy: one year observational follow-up study. Endocrine 2009; 36: 45-51.
32. Susantitaphong P, Siribamrungwong M, Doi K, Noiri E, Terrin N, Jaber BL: Performance of urinary liver-type fatty acid-binding protein in acute kidney injury: A meta-analysis. Am J Kidney Dis 2013; 61: 430-439.
33. Kamijo A, Sugaya T, Hikawa A, et al: Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease. Mol Cell Biochem 2006; 284: 175-182.
34. Yamamoto T, Noiri E, Ono Y, et al: Renal Ltype fatty acid-binding protein in acute ischemic injury. J Am Soc Nephrol 2007; 18: 2894-2902.
35. Portilla D, Dai G, Peters JM, Gonzalez FJ, Crew MD, Proia AD: Etomoxir-induced PPARalpha-modulated enzymes protect during acute renal failure. Am J Physiol Renal Physiol 2000; 278:F667-F675.
36. Parikh CR, Jani A, Melnikov VY, Faubel S, Edelstein CL: Urinary interleukin-18 is a marker of human acute tubular necrosis. Am J Kidney Dis 2004; 43: 405-414.
37. Anders HJ, Muruve DA: The inflammasomes in kidney disease. J Am Soc Nephrol 2011; 22: 1007-1018.
38. Iyer SS, Pulskens WP, Sadler JJ, et al: Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome. Proc Natl Acad Sci U S A 2009; 106: 20388-20393.
39. Wu H, Craft ML, Wang P, et al: IL-18 contributes to renal damage after ischemia-reperfusion. J Am Soc Nephrol 2008; 19: 2331-2341.
40. Homsi E, Janino P, de Faria JB: Role of caspases on cell death, inflammation, and cell cycle in glycerol-induced acute renal failure. Kidney Int 2006; 69: 1385-1392.
41. Yano T, Nozaki Y, Kinoshita K, et al: The pathological role of IL-18Rα in renal ischemia/reperfusion injury. Lab Invest 2015; 95: 78-91.
42. Witzgall R, Brown D, Schwarz C, Bonventre JV: Localization of proliferating cell nuclear antigen, vimentin, c-Fos, and clusterin in the postischemic kidney. Evidence for a heterogenous genetic response among nephron segments, and a large pool of mitotically active and dedifferentiated cells. J Clin Invest 1994; 93: 2175-2188.
43. Price PM, Safirstein RL, Megyesi J: The cell cycle and acute kidney injury. Kidney Int 2009; 76: 604-613.
44. Sharfuddin AA, Molitoris BA: Pathophysiology of ischemic acute kidney injury. Nat Rev Nephrol 2011; 7: 189-200.
45. Yang L, Besschetnova TY, Brooks CR, Shah JV, Bonventre JV: Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med 2010; 16: 535-543, 531p following 143.
46. Kashani K, Al-Khafaji A, Ardiles T, et al: Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care 2013; 17:R25.
47. Wetz AJ, Richardt EM, Wand S, et al: Quantification of urinary TIMP-2 and IGFBP-7: an adequate diagnostic test to predict acute kidney injury after cardiac surgery? Crit Care 2015; 19: 3.
48. Yamashita T, Doi K, Hamasaki Y, et al: Evaluation of urinary tissue inhibitor of metalloproteinase-2 in acute kidney injury: A prospective observational study. Crit Care 2014; 18: 716.
49. Hoste EA, McCullough PA, Kashani K, et al: Derivation and validation of cutoffs for clinical use of cell cycle arrest biomarkers. Nephrol Dial Transplant 2014; 29: 2054-2061.
50. Bihorac A, Chawla LS, Shaw AD, et al: Validation of cell-cycle arrest biomarkers for acute kidney injury using clinical adjudication. Am J Respir Crit Care Med 2014; 189: 932-939.
51. Meersch M, Schmidt C, Van Aken H, et al: Urinary TIMP-2 and IGFBP7 as early biomarkers of acute kidney injury and renal recovery following cardiac surgery. PLoS One 2014; 9:e93460.
52. Yang L, Humphreys BD, Bonventre JV: Pathophysiology of acute kidney injury to chronic kidney disease: maladaptive repair. Contrib Nephrol 2011; 174: 149-155.
53. Langenberg C, Bagshaw SM, May CN, Bellomo R: The histopathology of septic acute kidney injury: A systematic review. Crit Care 2008; 12:R38.
54. Canaud G, Bonventre JV: Cell cycle arrest and the evolution of chronic kidney disease from acute kidney injury. Nephrol Dial Transplant 2015; 30: 575-583.
55. Grgic I, Campanholle G, Bijol V, et al: Targeted proximal tubule injury triggers interstitial fibrosis and glomerulosclerosis. Kidney Int 2012; 82: 172-183.
56. Matsui K, Kamijo-Ikemori A, Hara M, et al: Clinical significance of tubular and podocyte biomarkers in acute kidney injury. Clin Exp Nephrol 2011; 15: 220-225.
57. Cianciolo Cosentino C, Skrypnyk NI, Brilli LL, et al: Histone deacetylase inhibitor enhances recovery after AKI. J Am Soc Nephrol 2013; 24: 943-953.
58. Zhou L, Fu P, Huang XR, Liu F, Lai KN, Lan HY: Activation of p53 promotes renal injury in acute aristolochic acid nephropathy. J Am Soc Nephrol 2010; 21: 31-41.
59. Humphreys BD, Lin SL, Kobayashi A, et al: Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol 2010; 176: 85-97.
60. Eardley KS, Kubal C, Zehnder D, et al: The role of capillary density, macrophage infiltration and interstitial scarring in the pathogenesis of human chronic kidney disease. Kidney Int 2008; 74: 495-504.
61. Eitner F, Bucher E, van Roeyen C, et al: PDGF-C is a proinflammatory cytokine that mediates renal interstitial fibrosis. J Am Soc Nephrol 2008; 19: 281-289.
62. Au P, Tam J, Duda DG, et al: Paradoxical effects of PDGF-BB overexpression in endothelial cells on engineered blood vessels in vivo. Am J Pathol 2009; 175: 294-302.
63. Lin SL, Chang FC, Schrimpf C, et al: Targeting endothelium-pericyte cross talk by inhibiting VEGF receptor signaling attenuates kidney microvascular rarefaction and fibrosis. Am J Pathol 2011; 178: 911-923.
64. Castano AP, Lin SL, Surowy T, et al: Serum amyloid P inhibits fibrosis through Fc gamma R-dependent monocyte-macrophage regulation in vivo. Sci Transl Med 2009; 1: 5ra13.
65. Huen SC, Cantley LG: Macrophage-mediated injury and repair after ischemic kidney injury. Pediatr Nephrol 2015; 30: 199-209.
66. Akcay A, Nguyen Q, Edelstein CL: Mediators of inflammation in acute kidney injury. Mediators Inflamm 2009; 2009: 137072.
67. Bonventre JV, Yang L: Cellular pathophysiology of ischemic acute kidney injury. J Clin Invest 2011; 121: 4210-4221.
68. Awad AS, Rouse M, Huang L, et al: Compartmentalization of neutrophils in the kidney and lung following acute ischemic kidney injury. Kidney Int 2009; 75: 689-698.
69. Lerolle N, Nochy D, Guerot E, et al: Histopathology of septic shock induced acute kidney injury: apoptosis and leukocytic infiltration. Intensive Care Med 2010; 36: 471-478.
70. Kinsey GR, Sharma R, Okusa MD: Regulatory T cells in AKI. J Am Soc Nephrol 2013; 24: 1720-1726.
71. Kinsey GR, Huang L, Jaworska K, et al: Autocrine adenosine signaling promotes regulatory T cell-mediated renal protection. J Am Soc Nephrol 2012; 23: 1528-1537.
72. Gigliotti JC, Huang L, Ye H, et al: Ultrasound prevents renal ischemia-reperfusion injury by stimulating the splenic cholinergic anti-inflammatory pathway. J Am Soc Nephrol 2013; 24: 1451-1460.
73. Bajwa A, Huang L, Kurmaeva E, et al: Sphingosine 1-phosphate receptor 3-deficient dendritic cells modulate splenic responses to ischemia-reperfusion injury. J Am Soc Nephrol 2015;pii:ASN.2015010095.
74. Pike F, Murugan R, Keener C, et al: Biomarker enhanced risk prediction for adverse outcomes in critically ill patients receiving RRT. Clin J Am Soc Nephrol 2015; 10: 1332-1339.
75. Ding Y, Choi ME: Regulation of autophagy by TGF-β: emerging role in kidney fibrosis. Semin Nephrol 2014; 34: 62-71.
76. Livingston MJ, Dong Z: Autophagy in acute kidney injury. Semin Nephrol 2014; 34: 17-26.
77. Kim SI, Na HJ, Ding Y, Wang Z, Lee SJ, Choi ME: Autophagy promotes intracellular degradation of type I collagen induced by transforming growth factor (TGF)-β1. J Biol Chem 2012; 287: 11677-11688.
78. Argiles A, Siwy J, Duranton F, et al: CKD273, a new proteomics classifier assessing CKD and its prognosis. PLoS One 2013; 8:e62837.
79. Schanstra JP, Zurbig P, Alkhalaf A, et al: Diagnosis and prediction of CKD progression by assessment of urinary peptides. J Am Soc Nephrol 2015; 26: 1999-2010.
80. Najbauer J, Johnson BA, Young AL, Aswad DW: Peptides with sequences similar to glycine, arginine-rich motifs in proteins interacting with RNA are efficiently recognized by methyltransferase(s) modifying arginine in numerous proteins. J Biol Chem 1993; 268: 10501-10509.
81. Tang J, Frankel A, Cook RJ, et al: PRMT1 is the predominant type I protein arginine methyltransferase in mammalian cells. J Biol Chem 2000; 275: 7723-7730.
82. Ogawa T, Kimoto M, Sasaoka K: Occurrence of a new enzyme catalyzing the direct conversion of NG,NG-dimethyl-L-arginine to L-citrulline in rats. Biochem Biophys Res Commun 1987; 148: 671-677.
83. Nakayama Y, Ueda S, Yamagishi S, et al: Asymmetric dimethylarginine accumulates in the kidney during ischemia/reperfusion injury. Kidney Int 2014; 85: 570-578.
84. Sharma M, Zhou Z, Miura H, et al: ADMA injures the glomerular filtration barrier: role of nitric oxide and superoxide. Am J Physiol Renal Physiol 2009; 296: F1386-F1395.
85. Fliser D, Kronenberg F, Kielstein JT, et al: Asymmetric dimethylarginine and progression of chronic kidney disease: The mild to moderate kidney disease study. J Am Soc Nephrol 2005; 16: 2456-2461.
86. Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C: Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: A competing risks modeling approach. J Am Soc Nephrol 2005; 16: 2449-2455.
87. Hanai K, Babazono T, Nyumura I, et al: Asymmetric dimethylarginine is closely associated with the development and progression of nephropathy in patients with type 2 diabetes. Nephrol Dial Transplant 2009; 24: 1884-1888.
88. Kielstein JT, Boger RH, Bode-Boger SM, et al: Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 2002; 13: 170-176.
89. Alge JL, Karakala N, Neely BA, et al: Urinary angiotensinogen and risk of severe AKI. Clin J Am Soc Nephrol 2013; 8: 184-193.
90. Alge JL, Karakala N, Neely BA, Janech MG, Velez JC, Arthur JM; SAKInet Investigators: Urinary angiotensinogen predicts adverse outcomes among acute kidney injury patients in the intensive care unit. Crit Care 2013; 17:R69.
91. Alge JL, Karakala N, Neely BA, et al: Association of elevated urinary concentration of renin-angiotensin system components and severe AKI. Clin J Am Soc Nephrol 2013; 8: 2043-2052.
92. Barrera-Chimal J, Perez-Villalva R, Rodriguez-Romo R, et al: Spironolactone prevents chronic kidney disease caused by ischemic acute kidney injury. Kidney Int 2013; 83: 93-103.
93. Yamamoto T, Nakagawa T, Suzuki H, et al: Urinary angiotensinogen as a marker of intrarenal angiotensin II activity associated with deterioration of renal function in patients with chronic kidney disease. J Am Soc Nephrol 2007; 18: 1558-1565.
94. Kobori H, Ohashi N, Katsurada A, et al: Urinary angiotensinogen as a potential biomarker of severity of chronic kidney diseases. J Am Soc Hypertens 2008; 2: 349-354.
95. Kobori H, Urushihara M: Augmented intrarenal and urinary angiotensinogen in hypertension and chronic kidney disease. Pflugers Arch 2013; 465: 3-12.
96. Allred AJ, Chappell MC, Ferrario CM, Diz DI: Differential actions of renal ischemic injury on the intrarenal angiotensin system. Am J Physiol Renal Physiol 2000; 279:F636-F645.